Along this line, trifunctional NK-cell engagers (NKCEs), consisting of two mAb fragments targeting the NK activating receptor NKp46 and a specific tumor antigen, joined to an Fc fragment optimized for CD16 binding, were shown to promote tumor clearance and improve NK cell tumor infiltration; notably, these constructs resulted more efficient than intact tumor-targeting mAbs in vivo in mouse models [175]. The gene discussed is FCGR3A; the disease is neoplasm.